FGP
ADMA icon

Freestone Grove Partners’s ADMA Biologics ADMA Stock Holding History

Freestone Grove Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$464K Buy
+51,455
New +$812K ﹤0.01% 609
2025
Q4 		– Sell
-30,519
Closed -$447K – 720
2025
Q3 		$447K Buy
+30,519
New +$523K ﹤0.01% 551
2025
Q1 		– Sell
-44,816
Closed -$769K – 574
2024
Q4 		$769K Buy
+44,816
New +$843K 0.01% 322

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Freestone Grove Partners's ADMA Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in ADMA Biologics (ADMA) in Q1 2026: 51,455 shares worth $464K. The stake represents ﹤0.01% of the portfolio and ranks #609 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in ADMA as recently as Q3 2025.

Freestone Grove Partners first reported a position in ADMA in Q4 2024 and has held it in 3 quarters since. The position peaked at $769K in Q4 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Freestone Grove Partners held 51,455 shares of ADMA Biologics worth $464K as of Q1 2026.
  • ADMA Biologics was a new Freestone Grove Partners position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #609 holding.
  • Freestone Grove Partners first reported a position in ADMA Biologics in Q4 2024 and has held it in 3 quarters since.
  • Freestone Grove Partners's ADMA Biologics position peaked at $769K in Q4 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.